The DC3 subset may be crucial for tumor immunity and is capable of inducing autologous naïve CD4+ helper T cell responses and IL-17 production, as well as activating CD8+ T cells, with lower efficiency than cDC2s [35, 42, 47]. This evidence concerns the gene CD4 and neoplasm.